Big Data Course Week 7 Test2Learn TM 5/7/16
|
|
- Marilynn Bates
- 6 years ago
- Views:
Transcription
1 The site is Usernames are first letter of first-name + first 3 letters of last name (i.e. John Smith would be jsmi ) Passwords are the same as the usernames. Everyone will need to accept the terms of use, after which they will be prompted to change their password Either connect your account to 23andMe or use an anonymous real genetic dataset 1
2 Phenotyping prediction: tasting exercise 1931 Arthur Fox discovery of variance in taste perception of phenylthiocarbamide (PTC) PTC is a chemical similar to bitter chemicals in vegetables, coffee, dark beers. Some people are unable to taste it ( taste blind or nontasters). Let s repeat his experiment using PTC impregnated paper and share our data Fox, AL. Proc. Natl. Acad. Sci. USA : Identify your patient s TAS2R38 genotype and predicted phenotype (presence of at least one C at rs713598) 2
3 Phenotype Genotype 33% 35.1% 26.3% 67% 38.6% Yes No GG GC CC Did the strip taste bitter to you? Yes = 67% (n = 117) TAS2R38 GG or GC = 64.9% (n = 57) What are some reasons the genotype and phenotype might not match? 3
4 Genetic basis of taster phenotype It s been used as a simple example of Mendelian inheritance (eg. tasting as autosomal dominant). Variation in the TAS2R38 gene accounts for 55 85% of the variation in PTC sensitivity. John McDonald, The Myth of PTC testing Pharmacogenomics: Clinical Decision Making James Stevenson, PharmD, MS Assistant Professor of Pharmacy & Therapeutics 4
5 CYP2D6: best understood MR = Meyer UA. Nat Rev Genet. 2004;5(9): PGx decision making Important factors to consider: 1. functional consequence 2. variant frequency in population eg. rs GA? 5
6 Group 1: Answer the following about the SNP rs : In what gene is it located and what is the function? What haplotype (star nomenclature) is associated with this SNP? Are there any reported functional consequences associated with this SNP/haplotype? Group 2: Answer the following about CYP2D6: What types of genetic variation are known to occur in this gene? What drugs do genetic variations in CYP2D6 impact? What is phenocopying and what are its clinical implications? Group 3: Answer the following about allopurinol: What haplotype is associated with allopurinol response? Do any clinical guidelines recommend using genetic test results in practice? Is the risk haplotype more common in some racial groups than others? Group 4: Answer the following about citalopram: What gene(s) have clinical guidelines that can be applied to citalopram? What other genes have been studied for association with citalopram response? Group 1 6
7 Group 1 What haplotype (star nomenclature) is associated with this SNP? Group 2 What types of genetic variation are known to occur in this gene? alleles that led to a complete loss of CYP2D6 activity reduced function and even hyperfunctional CYP2D6 alleles The CYP2D6 copy number has been found to be from Each functional copy of CYP2D6 that is present increases the rate of metabolism of CYP2D6 substrates significantly 7
8 Group 2 What drugs do genetic variations in CYP2D6 impact? What is phenocopying and what are its clinical implications? Group 3 What haplotype is associated with allopurinol response? Do any clinical guidelines recommend using genetic test results in practice? Is the risk haplotype more common in some race groups than others? 8
9 Group 4 What gene(s) have clinical guidelines that can be applied to citalopram? What other genes have been studied for association with citalopram response? PGx decision making Important factors to consider: 1. functional consequence 2. variant frequency in population 3. drug dependence on pathway Metabolite A Enzyme 1 Enzyme 2 Drug 80% 5% Metabolite B Enzyme 3 5% Metabolite A conjugate Excreted 9
10 Active moiety and therapeutic index Parent Drug Enzyme Metabolite PM/IM EM UM If parent drug is active moiety If metabolite is active moiety Parent Metabolite Toxicity Metabolite Parent Efficacy Metabolite Parent Failure Failure Efficacy Toxicity Empey PE. Crit Care Med (6 Suppl):S PGx decision making Important factors to consider: 1. functional consequence 2. variant frequency in population 3. drug dependence on pathway 4. active moiety and therapeutic index 5. concomitant drug therapy (DIs) and clinical factors 6. Is there clinical outcome data? What do established guidelines recommend? 10
11 CPIC Guidelines Level definitions for CPIC Gene/Drug Pairs CPIC, 10/2014 PGx decision making Important factors to consider: 1. functional consequence 2. variant frequency in population 3. drug dependence on pathway 4. active moiety and therapeutic index 5. concomitant drug therapy (DIs) and clinical factors 6. Is there clinical outcome data? What do established guidelines recommend? 7. Are tests available? Relative to PK/PD, the impact of PGx on PK (eg. drug metabolizing enzymes) is best understood. WHY? 11
12 Genetics loads the gun and environment pulls the trigger. Dr. Francis Collins Genetics Environ ment Trigger Outcome For chronic health conditions especially Genetics is predictive, not deterministic! Pathway Genetics Newsroom, 8/10/2010, accessed 10/2014 Pharmacogenomics: Predicting phenotype from variant level data Solomon Adams, PharmD Clinical Pharmacogenomics Fellow Graduate Student, Pharmaceutical Sciences 12
13 Identify your patient s CYP2C19 genotype and predicted phenotype Haplotype rs rs rs rs rs rs rs rs rs rs *1 G G A C G T T G C C *2 A *3 A *4A G *4B G T *5 T *6 A *7 A *8 C *9 A *10 T *17 T 13
14 CYP2C19 COMMON ALLELES Allele dbsnp Nucleotide* Protein** Effect %MAF (EU/AA/ALL) *1 None No variant None Normal 62.2/57.9/68.4 *2 rs c.681g>a Splicing Defect Loss of function 14.8/16.5/15.4 *3 rs c.636g>a p.trp212* Loss of function 0.02/0.05/0.03 *4 rs c.1a>g p.met1leu Loss of function 0.33/0.02/0.22 *5 rs c.1297c>t p.arg433trp Loss of function 0.0 *6 rs c.395g>a p.arg132gln Loss of function 0.05/0.02/0.04 *7 rs c.819+2t>a Splicing Defect Loss of function 0.0 *8 rs c.358t>c p.trp120arg Loss of function 0.20/0.14/0.18 *9 rs c.431g>a p.arg144his Unknown 0.0/1.16/0.39 *10 rs c.680c>t p.pro227leu Unknown 0.0/0.23/0.08 *17 rs c.-806c>t Promoter Increased transcription 22.4/23.5/15.3 Allele *1 *2 *3 *4 *5 *6 *7 *8 *9 *10 *17 *1 EM IM IM IM IM IM IM IM IM IM UM *2 PM PM PM PM PM PM PM PM PM IM *3 PM PM PM PM PM PM PM PM IM *4 PM PM PM PM PM PM PM IM *5 PM PM PM PM PM PM IM *6 PM PM PM PM PM IM *7 PM PM PM PM IM *8 PM PM PM IM *9 PM PM IM *10 PM IM *17 UM EM: extensive (normal) metabolizer; IM: intermediate metabolizer; PM: poor metabolizer; UM: ultrarapid metabolizer Adapted from CPIC, 10/
15 Patient presents to Cath Lab P2Y12 inhibitor initiated CYP2C19 genotype testing (if not previously done) UM EM IM PM clopidogrel 75 mg daily ticagrelor 90 mg BID or prasugrel 10 mg daily How many had a dataset that was a: A. EM (extensive normal metabolizer)? B. IM (intermediate metabolizer)? C. PM (poor metabolizer)? D. UM (ultra-rapid metabolizer)? 15
16 16
17 Apply the CYP2C19 genotype and predicted phenotype and the PGx clinical decision making process to determine the relevance for other drugs: carbamazepine, omeprazole, phenytoin Important factors to consider: 1. functional consequence 2. variant frequency in population 3. drug dependence on pathway 4. active moiety and therapeutic index 5. concomitant drug therapy (DIs) and clinical factors 6. Is there clinical outcome data? What do established guidelines recommend? 7. Are tests available? 17
18 Application of the PGx clinical decision making process Gene: CYP2C19 Carbamazepine Omeprazole Phenytoin Functional Consequences to Variation Variant Frequency Drug Dependent on Pathway Active moiety and Therapeutic Index Drug-Drug Interactions and Clinical Factors Outcome Data and/or Guidelines Exist Importa Active nt CPIC: No Partial Active Minor DPWG: Yes Partial, Minor Active Importa nt Available Tests Pharmacogenomics: Leading clinical applications Philip Empey, PharmD, PhD, BCPS Assistant Professor, Pharmacy & Therapeutics Associate Director for Pharmacogenomics, Institute of Personalized Medicine 18
19 TPMT & Thiopurines TPMT = Thiopurine methyl transferase TPMT & Thiopurines: is this really important? Heart transplant patient (later found thiopurine methyltransferase deficient) taking azathioprine 19
20 TPMT & Thiopurines FDA labeling of azathioprine recommends geno- or phenotyping: First CPIC guideline, 3/2011 (updated 2/2013) Relling et al. Clin Pharmacol Ther. 2011:89 3, Relling et al. Clin Pharmacol Ther. 2013: 93(4): Simvastatin & SLCO1B1 Myopathy is a rare, but serious, ADR. Monitoring is routinely performed. SLCO1B1 is the simvastatin hepatic uptake transporter 625 T>C (*5) has decreased activity Caucasian = 12 20% Asian = 6 19% A. American =1 4% Japanese =0.7% Kim et al. CP&T. 2005;78:
21 Simvastatin & SLCO1B1 SLCO1B1 variant = risk of simvastatin-induced myopathy Kim et al. CP&T. 2005;78: Link E et al. NEJM. 2008;359(8): Simvastatin & SLCO1B1 60% of myopathy cases attributed to *5 Risk 4.5 fold (1 copy); 16.9 fold (2 copies) Link et al. NEJM. 2008;359(8):
22 Simvastatin & SLCO1B1 Nothing in the FDA product label Statins & SLCO1B1 Why does the increased risk not extend to all drugs in class? Voora et al. J Am Coll Cardiol 2009;54(17):
23 Warfarin & CYP2C9/VKORC1 Commonly used anticoagulant with narrow therapeutic index, in top 10 drugs for ADRs Coagulation Polygenic PG issues: Genetic variants in both its metabolism and drug target M O R E Cavallari LH et al. Curr Opin Mol Ther 2009;11(3): CYP2C9/VKORC1 & Warfarin: dose requirements Daily Warfarin Dose (mg) 6 *1/*1 *1/*2 + *1/*3 *1/*3 *2/*2 *2/*3 + *3/* GG GA AA GG GA AA GG GA AA GG GA AA VKORC1 rs Genotype GG GA AA Adapted from: Sconce, et al. Blood. 2005;106(7) 23
24 CYP2C9/VKORC1 & Warfarin Together, account for 30 40% of variability in doses Gage/International Warfarin Consortium algorithms better than fixed dose or clinical variables only especially for those requiring <21 mg/wk or >49 mg/wk FDA updated labeling in 2007 and 2010, but did not mandate testing Gage et al. CP&T. 2008;84(3): Klein et al. NEJM. 2009;360(8): CYP2C9/VKORC1 & Warfarin Warfarindosing.org Verschuren et al. Eur Heart J (2012) 33 (2):
25 Warfarin case Ian M. Ableider is a 68 year old 5 8, 84 kg nonsmoking Caucasian male who was stable on warfarin 4 mg daily 2 years ago for Afib and was cardioverted. Today he is being restarted on warfarin for new onset of Afib to achieve a target INR of 2.5. PGx: VKORC AG & CYP2C9 *3/*3 Labs: INR 1.1; normal renal/liver function Meds: Simvastatin 20 mg daily Amiodarone 200 mg daily Lisinopril 10 mg daily Metformin 500 mg BID Paroxetine 20 mg daily 25
26 CYP2C9/VKORC1 & Warfarin: Latest data COAG (n=1015) 4 weeks 45.2% vs 45.4% p = 0.91 EU-PACT (n=455) TTR through 12 wks 67.4 vs 60.3% p < EU-PACT (n=548) TTR through 12 wks 61.6 vs 60.2% p = 0.52 GIFT is ongoing Kimmel et al. NEJM. 2013; 369: Pirmohamed et al. NEJM. 2013; 369: Talitha et al. NEJM. 2013; 369: Identify your patient s genotypes and predicted phenotypes using the interpretation engine Patient case application 26
27 Patient case HF is a 54 y/o asian male that presented to your hospital 2 days ago with c/o of severe substernal chest pressure, diaphoresis, and feeling of impending doom. He was diagnosed with STEMI and taken to the cath lab for primary PCI. He was found to have a 100% occlusion of his left anterior descending artery and a drug eluting stent (DES) was placed. His/Her clinical course was complicated by new onset atrial fibrillation. Discharge medications include: ASA 81 mg daily clopidogrel 75 mg dao;u Metoprolol 50 mg bid Carbamazepine 200 mg daily Lisinopril 10 mg daily simvastatin 20 mg daily Omeprazole 20 mg daily Warfarin 7.5 mg daily (has received one dose of 10 mg so far) Pre emptive PGx test results on file: CYP2C19 CYP2C9 SLCO1B1 VKORC1 DINNER BREAK 27
28 Pharmacogenomics: Applications to Community Rx Lucas Berenbrok, PharmD Assistant Professor of Pharmacy & Therapeutics Prescribing Transmission Dispensing Administration Monitoring 28
29 Case Report 65 yo male Presenting with Rx for clopidogrel post MI/PCI CYP2C19 genotyping offered to patient by community pharmacist Results: *1/*2 Prasugrel 10 mg once daily recommended by pharmacist to replace clopidogrel Drug therapy accepted by prescribing physician J Pharm Pract Feb 13;27(4): Test American Pharmacists Association 29
30 ACCESS PAYMENT CARE Nationwide Chains Regional Chains Independent Community Pharmacy 30
31 PATIENT PHARMACIST PHYSICIAN 31
32 Data Evidenced-based medication use Better health outcomes Current models partner with community pharmacists to optimize medication use. Patients are engaged via direct-to-consumer tests available at community pharmacies. Pharmacists may contribute to the PGx Tipping Point as connectors and mavens to pharmacogenomic data informing safe and effective medication use. 32
Utility of Pharmacogenomics to Identify and Limit CV Risk. Christopher B. Granger, MD
Utility of Pharmacogenomics to Identify and Limit CV Risk Christopher B. Granger, MD Disclosure Research contracts: AstraZeneca, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company, and Boehringer
More informationPharmacogenomics and Pharmacokinetics ^
Pharmacogenomics and Pharmacokinetics ^ avid F. Kisor, B.S., Pharm.. Profeor of Pharmacokinetics epartment of Pharmaceutical and Biomedical Sciences Raabe College of Pharmacy Ohio Northern University Learning
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationDeliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing
GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:
More informationWarfarin Dosing Using Genetic Information A Model for Hospital Policy Development
Warfarin Dosing Using Genetic Information A Model for Hospital Policy Development Jean Lopategui, MD Director, Molecular Pathology Jean.lopategui@cshs.org Warfarin Pharmacogenomics Part I Background Information
More informationPharmacogenomics of Cardiovascular Pharmacotherapies
Pharmacogenomics of Cardiovascular Pharmacotherapies Rhonda M. Cooper-DeHoff, Pharm.D., M.S., FCCP, FACC, FAHA University of Florida Gainesville, Florida Pharmacogenomics of Cardiovascular Pharmacotherapies
More informationCardiovascular pharmacogenomics: ready for prime time?
Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy,
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationINDIVIDUALIZED PATIENT THERAPY: IS IT MORE THAN A BUZZWORD?
INDIVIDUALIZED PATIENT THERAPY: IS IT MORE THAN A BUZZWORD? Kristin Wiisanen Weitzel, PharmD, FAPhA Clinical Associate Professor and Associate Chair, Pharmacotherapy and Translational Research, UF College
More informationTailoring Drug Therapy Based on Genotype. Larisa H. Cavallari, Pharm.D. Associate Professor, Department of Pharmacy Practice
Tailoring Drug Therapy Based on Genotype Larisa H. Cavallari, Pharm.D. Associate Professor, Department of Pharmacy Practice University of Illinois at Chicago 833 S. Wood St., Rm 164 Chicago, IL 60612 Tel:
More informationPharmacogenomics-based individualization of drug therapy
ETH Zurich-JST Workshop on Medical Research, 15 Sep 2008 Pharmacogenomics-based individualization of drug therapy Taisei Mushiroda, Ph.D. Laboratory for Pharmacogenetics Center for Genomic Medicine, RIKEN
More informationWarfarin Pharmacogenetics Reevaluated Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials
AJCP /ORIGINAL ARTICLE Warfarin Pharmacogenetics Reevaluated Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials Gary Stack, MD, PhD, 1,2 and Carleta
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationPharmacogenomics of Medications for Pain and Major Depression: Promise and Peril
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationPharmacogenomics with Clopidogrel: Does One Size Fit All?
Pharmacogenomics with Clopidogrel: Does One Size Fit All? Leah A. Sabato, PharmD PGY-1 Pharmacy Practice Resident UC Health - University of Cincinnati Medical Center leah.sabato@uchealth.com April 2015
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More informationObjectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017
Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics
More informationPharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy.
Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Objectives Review the concept of pharmacogenetics and pharmacogenomics
More informationCYP2D6 Genotype to Phenotype Standardization Project
CYP2D6 Genotype to Phenotype Standardization Project Project Objectives Determine a strategy for defining CYP2D6 phenotype based on genotype using a modified Delphi method. Standardize phenotype definitions
More informationPharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik
Maurizio Ferrari & Ron van Schaik Workshop IFCC Kuala Lumpur November 19, 2012 Predictive, Preventive and Personalized Medicine Part II: Pharmacogenetics l r.vanschaik@erasmusmc.nl Pharmacogenetics: DNA
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More informationClinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity
Clinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity Clinical Policy Number: 02.01.13 Effective Date: September 1, 2013 Initial Review Date: May 15, 2013 Most Recent Review
More informationHow to use pharmacogenetics to select patients for pharmaceutical care
How to use pharmacogenetics to select patients for pharmaceutical care Prof. Henk-Jan Guchelaar Dept. of Clinical Pharmacy & Toxicology Leiden University Medical Center University of Leiden PCNE Working
More informationImplementation of Pharmacogenomics in Clinical Medicine in the USA
Implementation of Pharmacogenomics in Clinical Medicine in the USA Dan M. Roden, MD Senior Vice President for Personalized Medicine Vanderbilt University Medical Center, Nashville, TN The vision "Here's
More informationSimon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of
Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy,
More information2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market
Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response
More informationImipramine therapy (CYP2D6)
Imipramine therapy (CYP2D6) Intake Start therapy 1st conc 08:00 2nd conc 3e spiegel 4e spiegel 1 week 1 week 1 week 1 week 1 week 22:00 ~ 50% patients need dose adjustment Imipramine therapy (CYP2D6) Intake
More informationSTEMI Presentation and Case Discussion. Case #1
STEMI Presentation and Case Discussion Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando, Florida September 17 th,
More informationJuly ACCP Cardiology PRN Journal Club 7/23/2018
July ACCP Cardiology PRN Journal Club 7/23/2018 Dr. Michael Plazak Dr. Michael Plazak is a PGY2 Cardiology Pharmacy Resident at the University of Maryland School of Pharmacy. He graduated from the University
More informationReview of Pharmacogenetic Testing Today
Review of Pharmacogenetic Testing Today Gwen McMillin, PhD ARUP Laboratories University of Utah Salt Lake City, Utah A customer says to the pharmacist: "Why does my medication have 40 side effects?" The
More informationPrior to starting the webinar. PharmGenEd : Bridging the Gap Between Science & Practice. Disclaimer. Train-the-Trainer Agenda 6/17/2014
Prior to starting the webinar Please make sure you have audio AND web features For audio, dial 866-740-1260 Enter access code 8223833 For video, go to www.readytalk.com Enter access code 8223833 To obtain
More informationPharmacogenomics: Genetic variations in drug metabolism and utilization. Disclosure
Pharmacogenomics: Genetic variations in drug metabolism and utilization Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP President, Fitzgerald Health Education Associates, North Andover,
More informationGENETICS OF STROKE: GETTING UP CLOSE AND PERSONAL December 8, 2017
GENETICS OF STROKE: GETTING UP CLOSE AND PERSONAL December 8, 2017 1 Faculty Disclosure Faculty: Guillaume Paré MD, MSc, FRCPC Associate Professor, McMaster University Senior Scientist, Population Health
More informationPersonalized Medicine in Real Time
LABORATORY OF PERSONALIZED HEALTH LPH Personalized Medicine in Real Time DNA-Guided Clopidogrel (Plavix ) Management Pharmacogenetic Foundations and Case Study 1 Clopidogrel (Plavix ) Leading AntiPlatelet
More informationNew Horizons in Anticoagulation: The Way of the Future. Disclosure. Outline. The speaker has nothing to disclose in relation to this presentation
New Horizons in Anticoagulation: The Way of the Future Gloria Grice Pharm.D., BCPS St. Louis College of Pharmacy & Barnes-Jewish Hospital Anticoagulation Service Disclosure The speaker has nothing to disclose
More informationImpact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan
More informationAndrea Jorgensen Department of Biostatistics/Wolfson Centre for Personalised Medicine, University of Liverpool
Andrea Jorgensen Department of Biostatistics/Wolfson Centre for Personalised Medicine, University of Liverpool Anticoagulant of choice in the UK Coumarin anticoagulant prescribed for: Venuous thrombosis
More informationSLCO1B1 Pharmacogenetic Competency
SLCO1B1 Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Which of the following is not currently a recognized SLCO1B1 phenotype? a) Low function b) Normal function c) Intermediate function
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More informationImplementing pharmacogenomics in Europe incentives & challenges
Implementing pharmacogenomics in Europe incentives & challenges Richard Turner Health Education England Genomics & Innovation Fellow Clinical Pharmacology & Therapeutics Registrar H2020, 15 million 10
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 12/16/10, 12/15/11, 12/20/12, 12/19/13, 12/18/14
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationComprehensive Drug Information for Smith, John
PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 42 Sex: Male SAMPLE Date Collected: March 21, 2016 Date Received: March 21, 2016 Case ID: CARDI16-000001 Source: Buccal Swabs Comprehensive
More informationPharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017
Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017 Atomoxetine Prescription CYP2D6 Genotype (AS = 0) (AS = 0.5 1.0) (As = 2.0) Ultrarapid (AS >2.0) Standard dose. Dose increase probably not necessary;
More informationImplémentation clinique de la pharmacogénétique
Implémentation clinique de la pharmacogénétique Vincent HAUFROID Cliniques Universitaires St Luc Université catholique de Louvain Louvain centre for Toxicology and Applied Pharmacology (LTAP) Pharmacogenetics:
More informationGan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur
Gan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur outline Definitions Genetic polymorphisms and drugs therapy a)warfarin b) Mercaptopurine c) Methotrexate d) Clopidogrel e) others
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationTwo decades of clinical pharmacogenetic testing - Where do we stand?
Two decades of clinical pharmacogenetic testing - Where do we stand? Marja-Liisa Dahl, MD PhD, Professor Dept of Clinical Pharmacology Karolinska University Hospital/Karolinska Institutet Stockholm, Sweden
More informationCore Data Set CYP2D6 Metabolism
Core Data Set CYP2D6 Metabolism Oxidised metabolites seen in pre-clinical species Inhibitor Target CYP Isoform CLint (µl/min/mg protein) % Inhibition Control 12.5 - Furafylline 1A2 12.9 0 Sulfaphenoxazole
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationPersonalized medicine: what does it mean to pharmacists?
Personalized medicine: what does it mean to pharmacists? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Associate professor, Faculty of Pharmacy,
More informationPharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT
PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D. 6777 Nancy Ridge Drive San Diego, CA 92121 US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN
More informationPharmacogenetics to tailor Drug Exposure and Outcomes in Kidney Transplantation
2017 BANFF-SCT Joint Scientific Meeting BARCELONA 27-31 March 2017 SCT Plenary 4 Thursday March 30, 2017 Pharmacogenetics to tailor Drug Exposure and Outcomes in Kidney Transplantation Dennis A. Hesselink
More informationImplementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories
Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic
More informationMEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 (CYP2C9) AND VITAMIN K EPOXIDE REDUCTASE SUBUNIT CI (VKORC) THAT AFFECT RESPONSE TO WARFARIN
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationPersonalized Medicine: Pharmacogenetics From Bench to Bedside and Beyond
Personalized Medicine: Pharmacogenetics From Bench to Bedside and Beyond Nita A. Limdi, Pharm.D, PhD, MSPH Professor of Neurology Interim Director, Personalized Medicine Institute Disclosure: Conflict
More informationThe Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (5), Page
The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (5), Page 6646-6654 The Impact of "CYP2C9" and "VKORC1" Genetic Polymorphism upon Oral Anticoagulation Requirements Hossam Yousef Kamal
More informationRon van Schaik. Pharmacogenetics. London, Oct 8-9, Clinical implementation: a 7 year experience
Ron van Schaik Associate Professor Pharmacogenetics Eur Clin Chem / Advisor EMA - PGWG London, Oct 8-9, 2012 Pharmacogenetics Clinical implementation: a 7 year experience Pharmacogenetics Core Laboratory*
More informationCardiovascular Health. Heart Disease / Atrial Fibrillation. Hypertension
P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142 TEST PATIENT Sex : D Collected : 00-00-0000 111 ROAD TEST SUBURB AB : 00000000 UR#:0000000 TEST PHYSICIAN DR JOHN DOE 111 CLINIC
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationPerceived challenges in genomic-based drug development. Garret A. FitzGerald University of Pennsylvania
Perceived challenges in genomic-based drug development Garret A. FitzGerald University of Pennsylvania Genomics Based Personalization of Medicine A Case in Point in Cancer Aside from emerging resistance.
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationKeywords: clopidogrel, genotype, inpatient, pharmacists, pharmacogenetics,
Implementation of inpatient models of pharmacogenetics programs Larisa H. Cavallari, Pharm.D., Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida,
More informationCost is not a barrier to implementing clopidogrel pharmacogenetics. Larisa H. Cavallari, Pharm.D., and Glen T. Schumock, Pharm.D., M.B.A.
Cost is not a barrier to implementing clopidogrel pharmacogenetics Larisa H. Cavallari, Pharm.D., and Glen T. Schumock, Pharm.D., M.B.A. From the Department of Pharmacy Practice (both authors), and the
More informationThiopurine S-Methyltransferase (TPMT): Pharmacogenetic Competency
Thiopurine S-Methyltransferase (TPMT): Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Approximately 10% of patients have a (an) TPMT phenotype. a) Normal/high function b) Intermediate
More informationPsychiatric genomics 2018: what the clinician needs to know
Li_benefit VPA_benefit cbz_benefit Lam_benefit Combo_ms_benefit Olz_benefit Cloz_benefit Ris_benefit Quet_benefit Ari_benefit Zip_benefit Asen_benefit Luras_benefit Pali_benefit Fluphen_benefit Haldol_benefit
More informationThrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
More informationPersonalized Genomic Medicine: What is it? Why should I care? How can I use it?
Friday, October 17, 2014 Olli Lifelong Learning Health Education Series Lunch and Learn UNC-Asheville Campus Lynn G. Dressler, Dr.P.H. Director, Personalized Medicine Mission Health Fullerton Genetics
More informationPharmacogenomics: Assessment of Therapeutic Risk vs Benefit
Pharmacogenomics: Assessment of Therapeutic Risk vs Benefit Lawrence J. Lesko Clinical Professor Center for Pharmacometrics and Systems Pharmacology University of Florida at Lake Nona November 15, 2016
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationPrecision Medicine Under the Big Sky
Precision Medicine Under the Big Sky Erica L. Woodahl, Ph.D. Associate Professor Department of Biomedical and Pharmaceutical Sciences University of Montana Disclosure Statement Presenter has no financial
More informationPersonalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection. Lindsay S. Elliott, Pharm.D., CGP
Personalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection Lindsay S. Elliott, Pharm.D., CGP Disclosure I, Lindsay Elliott, am a pharmacy consultant for Genelex Corporation in conducting
More information6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents
More informationThe WARFARIN Study: Genetic Testing and Systems Reengineering to Support Personalized Medicine
The WARFARIN Study: Genetic Testing and Systems Reengineering to Support Personalized Medicine Elizabeth O. Ofili, M.D., M.P.H., F.A.C.C. Professor of Medicine and Chief of Cardiology Associate Dean, Clinical
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 12/16/10, 12/15/11, 12/20/12, 12/19/13
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationWhat hematologists should know about VerifyNow
What hematologists should know about VerifyNow Hematology fellows conference 12/13/2013 Presenter: Christina Fitzmaurice, MD, MPH Discussant: Daniel Sabath, MD, PhD HMC consult patient 54 yo woman admitted
More informationPharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC)
Pharmacogenetics Implementation at Cincinnati Children s Hospital Medical Center (CCHMC) Laura Ramsey, PhD Co-Director, Genetic Pharmacology Service Assistant Professor Divisions of Research in Patient
More informationJoint Meeting of Coronary Revascularization 8 th to 9 th December 2017
B Joint Meeting of Coronary Revascularization 8 th to 9 th December 2017 A Novel Clinical Application Combining Genotyping and Platetlet Function Testing In Patients With Acs - A Case Series Shirley Tan
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationPharmacogenomics: application to the management of cardiovascular disease
Pharmacogenomics: application to the management of cardiovascular disease Julie A. Johnson, Pharm.D. 1, Larisa H. Cavallari, Pharm.D. 2, Amber L. Beitelshees, Pharm.D., MPH 3, Joshua P. Lewis, Ph.D. 3,
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationOral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,
More informationA PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI)
A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) Sony Tuteja, PharmD, MS Twitter @sony_tuteja Perelman School of Medicine at the University
More informationUSING GENETICS TO DRIVE TREATMENT: A FOCUS WARFARIN
Volume 23, Issue 10 July 2008 USING GENETICS TO DRIVE TREATMENT: A FOCUS ON WARFARIN Gregory J. Welder, Pharm.D. candidate The use of genetics in health care has become a mechanism for identifying risk.
More informationShould Gene+cs Influence Medica+on Use? Mona Fiuzat, PharmD, FACC Assistant Professor of Medicine Duke University Medical Center
Should Gene+cs Influence Medica+on Use? Mona Fiuzat, PharmD, FACC Assistant Professor of Medicine Duke University Medical Center Popula(on Differences Gene(c informa(on of humans is 95-99% iden(cal The
More informationPsychiatric Pharmacogenomics: Introduction and Applications
Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral
More informationAnticoagulant Treatments for Special Patient Populations
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-pharmacy/anticoagulant-treatments-for-special-patientpopulations/3796/
More informationHealth economics and drug safety
Health economics and drug safety Professor Dyfrig Hughes FFRPS FBPhS FLSW Centre for Health Economics & Medicines Evaluation Bangor University, Wales @HughesDyfrig ADEs that are not reactions to a medicine
More informationDrug Gene Interactions: Inherent Variability In Drug Maintenance Dose Requirements
Drug Gene Interactions: Inherent Variability In Drug Maintenance Dose Requirements Paul Wester velt; Kihoon Cho; David R. Bright, PharmD; and David F. Kisor, PharmD Key words: drug gene interaction, pharmacogenetics,
More informationClinical Implementation of Pharmacogenetics Mary V. Relling, Pharm.D.
Clinical Implementation of Pharmacogenetics Mary V. Relling, Pharm.D. Actionable pharmacogenetic gene/drug pairs have been known for a long time Primaquine G6PD Codeine CYP2D6 Thiopurines TPMT 5FU DPYD
More informationClinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
nature publishing group Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy SA Scott 1, K Sangkuhl 2, EE Gardner 3, CM Stein
More informationCYP2D6: mirtazapine 2001/2002/2003
CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =
More informationDetermination of Genotypes from Phenotypes in Humans
Determination of Genotypes from Phenotypes in Humans NAME DATE An organism can be thought of as a large collection of phenotypes. A phenotype is the appearance of a trait and it determined by genes (genotype).
More informationExtract Rules of Personalized Warfarin Treatment Protocol to Improve Outcome based on Clinical and Genetic Characteristics
Extract Rules of Personalized Warfarin Treatment Protocol to Improve Outcome based on Clinical and Genetic Characteristics Chih-Lin Chi, PhD, MBA Assistant Professor, School of Nursing Core Faculty, Institute
More informationControversies in Anticoagulation
Controversies in Anticoagulation Katrina Babilonia, PharmD Pharmacy Clinical Specialist Anticoagulation University of Colorado Hospital Katrina.babilonia@uch.edu Patient Case: DS DS 67 y/o CC: Chest Pain
More information